The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity
Acta Paediatrica · 2025
DOI: 10.1111/apa.70400 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Acta Paediatrica, 2025. Verfasst von Elektra Tsivitanidou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Biosimilar Pharmaceuticals, Bevacizumab, Angiogenesis Inhibitors. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Aim
Biosimilar anti‐vascular endothelial growth factor agents are cheaper alternatives to current treatments, but their safety and efficacy are unknown. This review aims to evaluate the safety and efficacy of biosimilar anti‐vascular endothelial growth factors in the management of retinopathy of prematurity.
Methods
A systematic review of the current literature was undertaken to identify studies that reported safety and efficacy outcomes of intravitreal administration anti‐vascular endothelial growth factor biosimilars in preterm infants with retinopathy of prematurity. Data were synthesised to assess safety, success and retreatment rates using random forest plots.
Results
Five studies met the inclusion criteria (382 eyes); three studies used bevacizumab biosimilars (217 eyes) and two used ranibizumab biosimilars (118 eyes). The overall adverse event rate was 0.5%. The pooled treatment success rates were 65% (95% CI: 58%–71%) with bevacizumab biosimilars and 46% (95% CI: 2%–95%) with ranibizumab biosimilars. Five eyes (1%) in the whole cohort required surgery: four in the bevacizumab and one in the ranibizumab group.
Conclusions
Biosimilar anti‐vascular endothelial growth factor agents demonstrated safety and reasonable efficacy. Biosimilars are a cost‐effective alternative and may improve clinical outcomes in low‐income countries. Randomised controlled trials should compare biosimilars to their reference biologic. Trial Registration PROSPERO: CRD420251010789
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Princess Alexandra Hospital NHS Trust, Harlow, UK.
- Great Ormond Street Hospital NHS Trust, London, UK.
ORCID-Profile: Elektra Tsivitanidou, Abdullah Shakeel
Zitieren
APA
Tsivitanidou, E., Shakeel, A., & Warda, O. (2025). The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity. Acta Paediatrica. https://doi.org/10.1111/apa.70400
Vancouver
Tsivitanidou E, Shakeel A, Warda O. The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity. Acta Paediatrica. 2025. doi:10.1111/apa.70400
BibTeX
@article{Tsivitanidou2025,
author = {Tsivitanidou, Elektra and Shakeel, Abdullah and Warda, Omar},
title = {The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity},
journal = {Acta Paediatrica},
year = {2025},
doi = {10.1111/apa.70400}
}
EUVIMED